Current Studies:
-
The Goal: Evaluating an innovative once-daily oral medication (Orforglipron) for children and teens compared to standard weekly injections.
Who Qualifies: Children/teens (10–18 years) with Type 2 Diabetes, BMI > 85th percentile, currently using metformin or basal insulin.
Key Benefits: Expert endocrine monitoring, weight reduction and up to $800 in compensation.
Call [208-821-3067] or email [info@medresearchpartners.com] to discuss eligibility.
-
The Goal: A new approach to long-term weight management using an investigational oral compound.
Who Qualifies: Adults (18+) with a BMI of 30+ (or 27+ with weight-related health conditions).
Key Benefits: Professional lifestyle coaching, metabolic tracking, and up to $1,500 in compensation.
Call [208-821-3067] or email [info@medresearchpartners.com] to discuss eligibility.
-
The Goal: Evaluating a next-generation vaccine to expand protection against pneumonia, meningitis, and other severe infections.
Who Qualifies: Healthy infants aged 42–98 days.
Key Benefits: Advanced immune protection for your child (protection against 25 strains vs. today's 20 strain), all care at no cost, and up to $2,005 in compensation.
Call [208-821-3067] or email [info@medresearchpartners.com] to discuss eligibility.
-
The Goal: Extending immune protection for children who have already completed their primary vaccine series.
Who Qualifies: Healthy children (15 months – 5 years) who have completed their initial vaccination series.
Key Benefits: Advanced protection (protection against 25 strains vs. today's 20 strain), expert health monitoring, and up to $734 in compensation.
Call [208-821-3067] or email [info@medresearchpartners.com] to discuss eligibility.
-
The Goal: Testing a needle-free, oral dissolving tablet for moderate-to-severe migraine attacks in children and adolescents.
Who Qualifies: Youth (6–17 years) who experience 1–8 migraine attacks per month and weigh at least 33 lbs.
Key Benefits: Specialized headache expert care and up to $950 in compensation.
Call [208-821-3067] or email [info@medresearchpartners.com] to discuss eligibility.
-
The Goal: Investigating a long-acting metabolic agonist optimized to target and reduce deep belly fat (visceral adiposity).
Who Qualifies: Adults (18–75) with severe obesity or high visceral adiposity who have maintained a stable weight for at least 3 months.
Key Benefits: Professional metabolic health monitoring and up to $1,600 in compensation.
Call [208-821-3067] or email [info@medresearchpartners.com] to discuss eligibility.
-
The Goal: Evaluating the investigational injection, Eloralintide, for chronic knee joint pain in patients with weight-related health challenges.
Who Qualifies: Adults (18+) with confirmed knee osteoarthritis and a baseline pain score of 4+ (WOMAC scale).
Key Benefits: Free diagnostic knee X-rays, specialized lifestyle coaching, and up to $1,400 in compensation.
Call [208-821-3067] or email [info@medresearchpartners.com] to discuss eligibility.
-
The Goal: Evaluating an updated Measles, Mumps, and Rubella vaccine formulation for improved preventative coverage.
Who Qualifies: Healthy children aged 12–15 months (for dose 1) or 4–6 years (for dose 2).
Key Benefits: Expert pediatric care, all vaccines provided at no cost, and up to $350 in compensation.
Call [208-821-3067] or email [info@medresearchpartners.com] to discuss eligibility.
-
Description: A study to evaluate the safety and immune response of an investigational chickenpox (varicella) vaccine compared to the standard chickenpox vaccine, administered as a first dose to healthy toddlers 12 to 15 months of age. Participants will also receive other routine childhood vaccinations (MMR and Hepatitis A) during the study.
Qualifications:
Healthy male or female toddlers established by medical history and clinical examination.
Between, and including, 12 to 15 months of age (from the day of their 1st birthday until the day before they turn 16 months) at the time of vaccination.
Participants who have not previously received a vaccine for measles, mumps, rubella, hepatitis A, or chickenpox (varicella).
Participants with no history of chickenpox disease.
Participants will also be compensated up to $725 for time, travel, and participation. This gives participants the opportunity to receive study-related vaccinations and medical assessments at no cost.